Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
212M
-
Number of holders
-
183
-
Total 13F shares, excl. options
-
78.4M
-
Shares change
-
-4.14M
-
Total reported value, excl. options
-
$656M
-
Value change
-
-$35.5M
-
Put/Call ratio
-
2.2
-
Number of buys
-
77
-
Number of sells
-
-71
-
Price
-
$8.37
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q4 2019
222 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q4 2019.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 183 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 78.4M shares
of 212M outstanding shares and own 36.99% of the company stock.
Largest 10 shareholders include BlackRock Inc. (9.53M shares), VANGUARD GROUP INC (8.49M shares), WELLINGTON MANAGEMENT GROUP LLP (7.75M shares), WASATCH ADVISORS INC (7.49M shares), STATE STREET CORP (4.81M shares), Bellevue Group AG (3.85M shares), CREDIT SUISSE AG/ (2.47M shares), DIMENSIONAL FUND ADVISORS LP (2.18M shares), FMR LLC (2.02M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.58M shares).
This table shows the top 183 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.